Indivior PLC (NASDAQ:INDV) is one of the best performing pharma stocks in 2025. Indivior PLC (NASDAQ:INDV) announced its full ...

Milestones Include Top-Tier 3-Year Accreditations from OASAS and The Joint Commission, Staff Growth to Over 20 ...

Shares of Indivior (NASDAQ:INDV) climbed 4.5% in U.S. premarket trading on Thursday after the company issued fiscal 2026 ...

Total Net Revenue Expected in the Range of $1,125 million to $1,195 millionTotal SUBLOCADE- Net Revenue Expected to be in the Range of $905 million to $945 millionNon-GAAP Operating Expenses Expected ...

The mid-point of Indivior’s FY26 guidance suggests 3% upside to consensus group sales estimates and 3% upside to Sublocade sales forecasts. The company’s adjusted EBITDA guidance was particularly ...

Franklin County Municipal Court is now offering onsite treatment for monthly medication-assisted treatments for opioid ...

NASDAQ:ADMA: $10.83 million (8.81% of AUM) NASDAQ:EOLS: $9.43 million (7.67% of AUM) NASDAQ:ZVRA: $7.70 million (6.26% of AUM) NASDAQ:NKTR: $4.84 million (3.93% of AUM) As of Friday, Indivior shares ...

Of that total, Jefferies said about $60 million would come from outside the U.S., implying U.S. Sublocade revenue of roughly $840 million, compared with $775 million in 2025. Jefferies noted that ...

Medicaid and commercially insured patients with high adherence to SUBLOCADE® experienced lower relapse rates and reduced healthcare resource utilization Adherence to SUBLOCADE was associated with ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Indivior ( (INDV)) has provided an update ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...